Skip to main content
Clinical Trials/DRKS00020780
DRKS00020780
Completed
N/A

Evaluation of bone mineral density and bone metabolism during treatment with januskinaseinhibitors baricitinib or tofacintib in patients with rheumatoid arthritis

Campus Kerckhoff der Justus Liebig Universität Giessen, Abteiliung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin0 sites89 target enrollmentMarch 17, 2020
ConditionsM05.80M06.00

Overview

Phase
N/A
Intervention
Not specified
Conditions
M05.80
Sponsor
Campus Kerckhoff der Justus Liebig Universität Giessen, Abteiliung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin
Enrollment
89
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 17, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Campus Kerckhoff der Justus Liebig Universität Giessen, Abteiliung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin

Eligibility Criteria

Inclusion Criteria

  • Patients \> 18 years with moderate to severe active rheumatoid arthritis who are going to receive treatment with tofacitinib or baricitinib. The indication for treatment with either one of the JAKi needs to be given by the treating rheumatologist. Only patients with RA fulfilling the ACR/EULAR classification criteria are eligible.

Exclusion Criteria

  • Contraindications to treatment with tofacitinib or baricitinib.
  • Incompatible language barriers
  • Missing consent
  • During study: inadherence to pharmacological treatment

Outcomes

Primary Outcomes

Not specified

Similar Trials